EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in...
Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial...
Barchart Research What to Expect from LCTX Earnings LCTX Generated May 11, 2026 Current Price $1.3100 EPS Estimate $$-0.02 Consensus Rating Strong Buy Average Move 2.07% Lineage Cell Therapeutics Reports...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today...
Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD)...
Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions,...